[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hull University Teaching Hospitals NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":366},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,47,73,98,120,145,174,204,227,248,276,297,316,344],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630117","the-effects-of-a-6-week-pre-operative-administration-of-a-microbiome-modulator-wellbiome-versus-placebo-on-cardiac-surgical-outcomes-and-nhs-cost-savings-100630117",false,"NCT07483502","The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","A Double Blind, Placebo Controlled 6- Week Pre-operative Randomised Clinical Trial of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","INCLUSION CRITERIA:\n\n* Aged 50-80\n* BMI ≥ 25-40kg\u002Fm²\n* Waist circumference \\>94cm (men) and 88cm (women)\n* HbA1c 42-58 mmol\u002Fmol (6.0-7.5 old HbA1c units)\n* No known intolerances to oligosaccharides and xylooligosaccharides\n* Be stable dose of cholesterol and blood pressure medication for 3 months\n* Be willing to participate and sign to that effect.\n\nEXCLUSION CRITERIA\n\n* Active cancer\n* Any gastro-intestinal surgery or currently under the care of the GI clinical team for any clinically significant digestive issue (Crohn's, IBS, ulcerative colitis).\n* On or had antibiotic treatment in the last 3 months.\n* Patients who have taken ibuprofen in the last week or any condition that increases the likelihood of regular or sustained use during the intervention.\n* On proton pump inhibitors (Omeprazole, Esomeprazole, Lansoprazole, Rabeprazole, Pantoprazole) within the last one month on long acting non-steroidal anti-inflammatory drugs in the last month or any condition that increases the likelihood of regular use during the intervention.\n* Taking any prebiotic or probiotic supplementation within the last three months\n* Patients who are vegetarians or vegans","ALL","50 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","More than 7.4 million people in the UK are currently waiting for surgery. Behind that number are real people-patients preparing mentally and physically for procedures ranging from joint replacements to major heart and abdominal operations.\n\nThis research forms part of a broader strategy known as prehabilitation - preparing the body before surgery to improve outcomes afterward. For patients waiting for surgery, it represents a shift from passive waiting to active preparation.\n\nHeart surgery for bypass or valve replacements results in inevitable yet controlled trauma. It increases inflammation, stress hormones and immune system demand. The body then has to repair itself - quickly and efficiently. And here's the surprising part. Inside your gut live trillions of bacteria - called your gut microbiome. These bacteria help regulate inflammation, strengthen your immune system and protect against infection.\n\nThis randomised clinical trial is investigating a fascinating question:\n\nCan improving your gut microbiome through consumption of fibre before surgery help you recover faster, reduce time in ICU, shorten hospital stays, and lower complication rates? The placebo controlled trial will randomise 80 patients following eligibiilty checks to either 5g of prebiotic fibre\u002F300mg of magnesium (WellBiome) OR 5g of maltodextrin for a period of 6-8 weeks prior to surgery. Patient will provide blood, urine and faecal samples at baseline and upon admission for surgery, and two further blood samples at day 3 and 6 post operatively.\n\nFollowing surgery, patient outcomes will be assessed and compared between the experimental group (prebiotic fibre\u002Fmagnesium) and placebo group (maltodextrin). The investigators are focussing on the time spent in the intensive care unit, complications and overall hospital stay. By documenting and quantifying these the investigators can calculate the costs and any savings between the groups.",[27,28],"Cardiovascular Diseases (CVD)","Cardiovascular Surgery",[30,31,32,33],"Cardiac surgery","Surgical outcomes","Nutritional prehabilitation","Microbiome","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":38},"2026-04-09",{"date":42,"type":21},"2026-12-18",{"name":44,"class":45},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100624429","nutritional-screening-in-cardiovascular-disease-100624429","NCT07409519","Nutritional Screening in Cardiovascular Disease","Nutritional Screening in Patients With Cardiovascular Disease","NS","Inclusion Criteria:\n\n• No pre-specified inclusion criteria to ensure we recruit a representative group of patients.\n\nExclusion Criteria:\n\n* All patients without proficiency in English that allows completion of questionnaires\n* Unable to provide written consent","40 Years","85 Years",{"count":58,"type":21},250,"OBSERVATIONAL","This is a nutritional screening and assessment study conducted prior to heart surgery. The nutritional status of patients will be assessed by a series of questionnaires, blood\u002Furine biomarkers and measurement of grip strength and body composition. The investigators will then evaluate of any of the assessments are linked with clinical outcomes following surgery. For example, how long do patients stop in the intensive care unit (ICU), in hospital and how many complications patients experience.\n\nThe investigators hope to use this important clinical data to understand how medical staff can identify a poor nutritional status and which patients may need nutritional support prior to surgery.",[62],"Cardiovascular Diseases",[64,65,30,66],"Nutrition","Screening","Clincial outcomes",{"date":37,"type":38},{"date":69,"type":38},"2025-08-20",{"date":71,"type":21},"2027-01-10",{"name":44,"class":45},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100583452","identification-of-b-regulatory-cells-by-flow-cytometry-100583452","NCT06876506","Identification of B Regulatory Cells by Flow Cytometry","Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy","Control cohort - Participants with:\n\n* No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms\n* Negative serological testing for specific IgE to pollens, house dust mite and insect venoms\n* Patients aged 18 years or older\n\nTest cohort:\n\n* Participants over the age of 18 years\n* Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom\n* Participants who are pregnant\n* Participants who cannot adequately understand verbal and \u002F or written explanations given in English",true,"18 Years",{"count":20,"type":21},"The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is;\n\n1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen.\n\nPatients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.",[85,86],"Pollen Allergy","Venom Allergy",[85,86,88,89,90],"Allergen Immunotherapy","B-regulatory cells","dust mite allergy","NOT_YET_RECRUITING",{"date":37,"type":38},{"date":94,"type":21},"2026-08-01",{"date":96,"type":21},"2027-09-30",{"name":44,"class":45},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100326955","tumour-regulatory-molecules-in-early-pancreatic-cancer-detection-100326955","NCT03536793","Tumour Regulatory Molecules in Early Pancreatic Cancer Detection","Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions","TEM-PAC","Inclusion Criteria:\n\nGeneral\n\n* Capable of giving written informed consent\n* Age ≥18 years\n\nPancreatic Cancer Cohort\n\n\\- Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or Whipple's procedure).\n\nOR - Diagnosed with inoperable localised pancreatic cancer and referred for further management (malignant control subgroup).\n\nPancreatic Cysts Cohort\n\n\\- Presence of cystic lesions where MDT have agreed further diagnostic intervention procedures (including FNA\u002FEUS) necessary.\n\nOR - Patient the MDT have agreed have resectable lesions suspicious for pancreatic malignancy and going to surgery.\n\nBenign Cohort\n\n\\- Referral for endoscopic cystogastrostomy for complicated acute pancreatitis characterised by peripancreatic fluid collections and pseudocysts in development or matured (non-resolving and requiring further intervention).\n\nOR\n\n* Referral for cholecystectomy for cholocystitis\u002Fchololethiasis. OR\n* Patient planned to have endoscopy investigation for dyspepsia (normal control subgroup).\n\nExclusion Criteria:\n\nGeneral\n\n* Inability to provide written informed consent\n* Other known malignant condition, either active or in complete remission ≤5 years\n* HIV, hepatitis C, or any other known communicable disease",{"count":107,"type":21},180,"The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pancreatic cancer, at a stage where surgery is feasible, would greatly increase the 5-year survival rate. Detecting pancreatic cancer early is therefore vital to improve the prognosis for these patients.\n\nPre-cancerous pancreatic cysts are an early indicator of malignant transformation. The ideal screening test would be capable of detecting pancreatic cancer at these initial stages. Current procedures for pancreatic cancer diagnosis are invasive, uncomfortable and costly, and can be considered unnecessary in those cysts found to be benign.\n\nWe propose to study a number of tumour regulatory molecules that have been the subject of research in laboratories at the University of Hull (e.g., tissue factor (TF), adrenomedullin (AM) using enzyme-linked immunosorbent assays (ELISA) tests) that have been studied in the context of carcinogenic transformation in more common malignancies but have yet to be fully tested in pancreatic malignant transformation. The recent introduction of platform technologies at the University of Hull has broadened this area of investigation by giving us access to next generation genomic sequencing and proteomic analyses of small amounts of tissue samples. We intend to analyse pancreatic cystic fluid samples using these technologies to discover new regulatory molecules.\n\nAltogether, his study will measure the levels of novel regulatory molecules and genetic changes involved with pancreatic cancer carcinogenesis using a combination of conventional techniques (e.g. ELISA) and state-of-the-art platform technologies in pancreatic cysts from those patients in whom cancer may be suspected, to determine the potential of these molecules to serve as markers to detect early changes towards pancreatic cancer.",[110,111],"Cancer of Pancreas","Pancreas Cyst",[113],"Early detection of pancreatic cancer",{"date":37,"type":38},{"date":116,"type":38},"2018-10-24",{"date":118,"type":21},"2029-02-28",{"name":44,"class":45},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":46},"100584049","phase-3-comparing-high-and-low-dose-iron-treatments-for-people-on-peritoneal-dialysis-the-paladin-study-100584049","NCT06884280","Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","Proactive High Dose Versus Low-dose Reactive Intravenous or Oral Iron in People on Peritoneal Dialysis (PALaDIN) - an Open-label, Feasibility Randomised Study","PALaDIN","Inclusion Criteria:\n\n* Males and females aged ≥18 years.\n* Able to give informed consent\n* Serum ferritin \\\u003C700ug\u002FL\n* Transferrin saturation level \\\u003C40%\n* No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week washout period)\n* Received maintenance peritoneal dialysis therapy for at least 4 weeks\n* Expected to remain on peritoneal dialysis therapy for duration of study\n\nExclusion Criteria:\n\n* Inadequate dialysis deemed by responsible clinician\n* Probability of need for transfusion within 1 week of enrolment\n* On or received a HIF-PHI in the past 4 weeks\n* Anticipated major surgery that the responsible clinician feels will impact response to treatment\n* Haemochromatosis \u002F haemosiderosis or ALT \\>x3 normal\n* Are deemed to be most suited to best-supportive or end-of-life care at time of screening\n* Women of childbearing potential not using effective means of contraception\n* Have been involved in another medicinal study (CTIMP) within past 4 weeks\n* Known allergy or adverse reaction to oral or intravenous iron preparations\n* CRP \\>50, TSATs \\>40%, SF \\>700 at time of recruitment\n* Active infection, HIV, active Hep B or C\n* Are unable or unwilling to consent to or complete the study procedures",{"count":129,"type":21},30,[131],"PHASE3","Chronic kidney disease affects a significant portion of the UK population, with approximately 3.5 million adults diagnosed. At its most severe stage, end-stage kidney disease, individuals require frequent dialysis treatment. One form of dialysis, known as peritoneal dialysis, involves introducing and removing fluid from the abdominal cavity to help filter out toxins from the body.\n\nThe kidneys are involved in various hormonal processes, including those responsible for producing red blood cells, making anaemia a common consequence of kidney failure. When designing a clinical trial to evaluate the effectiveness of any treatment, it is essential to determine the number of suitable and willing participants, as well as those who can complete all required tests and measurements. Identifying the most appropriate measurement to assess the impact of intravenous iron (iron injected directly into veins) is crucial to ensure that any observed changes are meaningful to people with CKD and their carers. To address these considerations, the investigators will conduct a pilot feasibility trial.\n\nIn this trial, individuals with kidney disease undergoing peritoneal dialysis will be randomly assigned to receive either high-dose or low-dose intravenous iron, or oral iron therapy. Over twelve months, the investigators will monitor their anaemia response, symptoms of kidney disease, quality of life, physical performance (such as the ability to walk for six minutes), and cognitive function. Additionally, the investigators will assess the impact of each intervention on the frequency of blood transfusions, whether those on oral iron require intravenous iron, and any changes in the dosage of erythropoietin-stimulating agents (drugs that increase blood production).",[134,135,136],"Peritoneal Dialysis","Anaemia","Iron Deficiency, Anaemia","2026-05-05",{"date":139,"type":38},"2026-05-06",{"date":141,"type":38},"2025-11-13",{"date":143,"type":21},"2027-10",{"name":44,"class":45},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100631542","impact-of-exercise-access-on-physio-outcomes-post-knee-replacement-100631542","NCT07502040","Impact of Exercise Access on Physio Outcomes Post Knee Replacement","A Feasibility Study To Determine The Effect Of An Artificial Intelligence (AI) Based Motion Tracking Exercise Programme (Kemtai) On Amount Of Physiotherapy Contact And Length Of Hospital Stay After Knee Arthroplasty Compared With Exercise As Usual .","KEMTAI","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Referred to Hull University Teaching Hospitals NHS Trust t for Knee Arthroplasty at either Castle Hill Hospital or Goole District Hospital and has access to pre operative resources offered by the joint school physiotherapists.\n3. Has access to a device which is compatible with the operational requirements of the Kemtai programme.\n4. Able to give informed consent.\n\nExclusion Criteria:\n\n• Significant comorbid physical or mental illness considered by the investigator to either: prevent engagement in modified exercise; impair the participants ability to follow instructions place the participant at undue risk during exercise training adversely affect the recovery or rehabilitation trajectory\n\n* Patients already involved in an exercise or rehabilitation study will be excluded from this study.\n* Unwilling or unable to consent or complete study measures.\n* Has insufficient understanding of English or the languages that are supported by the Kemtai programme and does not have someone who can translate.\n* Is a prisoner\n* Has had a total hip replacement within the previous 6 months.\n* Is attending for revision of a previous knee replacement\n* Is having a knee replacement due to a tumour\n* Lacks visual acuity sufficient to follow stimuli on monitor or has someone who can give necessary verbal prompts\n* Severe genu varum or genu valgum deformity which precludes the ability to exercise using the Kemtai programme.",{"count":154,"type":21},40,[24],"To stay strong, patients should do some strength training at least twice a week. However arthritic pain can limit walking and activity. The wait for knee surgery can be long, which can lead to loss of muscle strength. Patients who need a new knee joint tend to be older. If older people do not exercise and become weak, they tire easily, and may take longer to recover after surgery. Patients recover faster after having a new knee joint if their leg muscles are strong. This is why exercise before surgery can help people to make the most of their new joint. Patients come to a joint school where the investigators show them exercises and advise how to get ready for surgery. Patients are given a sheet of pictures and prompts for each exercise but the investigators know that some people don't do the exercises that they are given. Exercises are more likely to be done if they are fun, if people can see they make a difference, if they know what to do, and if their physiotherapist can check what they are doing.",[158],"Knee Arthroplasty, Total",[160,161,162,163,164,165],"Arthroplasty","Exercise","Prehabilitation","Motion-tracking","Digital App","Artificial intelligence","2026-03-24",{"date":168,"type":38},"2026-03-30",{"date":170,"type":21},"2026-03-31",{"date":172,"type":21},"2026-11-28",{"name":44,"class":45},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100630891","sacroplasty-for-sacral-insufficiency-fractures-100630891","NCT07493564","Sacroplasty for Sacral Insufficiency Fractures.","Sacroplasty for Sacral Insufficiency Fractures: a Randomised Controlled Trial.","SACRA","Inclusion Criteria:\n\n* Age 50 years or older\n* Low-energy sacral or posterior pelvic fracture confirmed on CT or MRI\n* Symptom duration ≤6 weeks with ongoing pain ≥48 hours\n* Suitable for sacroplasty under local anesthetic with optional sedation\n* Informed consent provided by participant or consultee agreement under the Mental Capacity Act 2005\n\nExclusion Criteria:\n\n* High-energy or unstable pelvic ring fracture requiring open fixation\n* Active infection or malignancy at fracture site\n* Uncorrectable coagulopathy or anatomy precluding safe sacroplasty\n* Life expectancy \\\u003C3 months\n* Participation in conflicting interventional trial\n* Previous sacroplasty\n* Patient not suitable for sacroplasty under local anesthetic with optional sedation",{"count":183,"type":21},78,[24],"This study is designed to determine whether sacroplasty, a minimally invasive procedure to stabilize sacral fractures, improves quality of life and functional recovery in adults aged 50 years or older with sacral or posterior pelvic fragility fractures. These fractures are common in older adults and can cause prolonged pain, reduced mobility, and an increased rate of mortality and risk of complications such as pneumonia, blood clots and pressure sores. Standard treatment usually involves pain management, physiotherapy and mobilization but recovery can be slow.\n\nParticipants will be randomly assigned to receive either sacroplasty under local anaesthetic (with optional sedation) performed by interventional radiologists or standard non-surgical care including analgesia and physiotherapy. Follow-up assessments will take place at 6 weeks and 6 months to evaluate pain, mobility, healthcare use, safety and overall quality of life.\n\nThe goal of the study is to provide evidence on whether sacroplasty can accelerate recovery, reduce complications and improve independence and quality of life in older adults with these fractures.",[187,188],"Sacral Fracture","Osteoporotic Fracture",[190,191,192,193,194,195],"sacroplasty","Sacral insufficiency fracture","Pelvic fragility fracture","Minimally invasive","Pain management","Functional recovery","2026-03-23",{"date":198,"type":38},"2026-03-25",{"date":200,"type":21},"2027-01",{"date":202,"type":21},"2030-12",{"name":44,"class":45},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100381403","a-randomised-control-trial-comparing-functional-outcomes-for-navigated-kinematically-aligned-tkr-versus-navigated-mechanically-aligned-tkr-100381403","NCT04246138","A Randomised Control Trial Comparing Functional Outcomes for Navigated Kinematically Aligned TKR Versus Navigated Mechanically Aligned TKR","RCT Comparing Functional Outcomes for Navigated Kinematically Aligned TKR Versus Navigated Mechanically Aligned TKR","MaKKRO","Inclusion Criteria:\n\n* • Age between 18 and 90 years\n\n  * Diagnosis of degenerative osteoarthritis\n\nExclusion Criteria:\n\n* o a)Post traumatic arthritis\n\n  * b)Varus \u002Fvalgus deformity of more than 20 degrees\n\n    * flexion contracture of more than 20 degrees\n    * reduced ability to make decision like dementia patients\u002Fchildren\n  * e)if they had undergone any orthopaedic procedure to the lower limbs within the last one year\n  * h) neuromuscular or neurosensory deficiency\n  * I)inflammatory arthritis of the knee joint\n\n    * patients who suffered a complication which might influence the final outcome such as a deep infection, fracture or dysfunction of the extensor mechanism in post-operative period. However the complication rate data will be analysed and reported.\n    * pregnancy\n    * patients involved in other clinical trials within last 6 months prior to being recruited in the study","90 Years",{"count":214,"type":21},100,[24],"The overall aim of the study is to compare navigated kinematically aligned total knee replacements (KA TKR) with navigated mechanically aligned TKR (MA TKR) in terms of function and ROM\n\nThe objectives are therefore:\n\n1. To compare the functional outcomes of KA TKR versus MA TKR performed using navigation technique\n2. To compare ROM and alignment of knee in the two groups",[218],"Kinematical Alignment,Mechanical Alignment, Navigation","2026-03-16",{"date":221,"type":38},"2026-03-18",{"date":223,"type":38},"2018-02-18",{"date":225,"type":21},"2026-12-31",{"name":44,"class":45},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":234,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100625816","palliative-care-and-the-terminally-ill-adults-end-of-life-bill-100625816","NCT07427550","Palliative Care and The Terminally Ill Adults (End of Life) Bill","The Potential Impact of the Terminally Ill Adults (End of Life) Bill on the Professional Identity of Palliative Care Staff","Inclusion Criteria:\n\n* Palliative care staff, including Palliative nurses, Doctors and Consultants.\n* Registered with the appropriate professional registration body\n* Must have been in qualified position and working in palliative care for at least 6 months\n* Must have worked with palliative patients in the last three months\n* Fluency in English\n\nExclusion Criteria:\n\n* No direct contact with patients\n* Must be in a directly caring role within the team (does not include administrative or housekeeping staff).",{"count":235,"type":21},6,"The current study aims to investigate the potential impact of the proposed Assisted Dying (Terminally Ill Adults (2024) Bill on Palliative care workers. Palliative care professionals across the Humber Health Partnership will be interviewed using semi-structured interview questions, with the intention of exploring the way they make sense of the potential implementation of the bill, particularly in relation to their professional identity. The research will be carried out in line with guidance for Interpretative Phenomenological Analysis (Smith, Flowers \\& Larkin, 2021), a research methodology which aims to explore how people make sense of their experience, often in response to a particular event.\n\nIt is hoped that the study will contribute to the ongoing discussions regarding how the bill should be implemented and offer potential insights into ways that hospitals may best support staff during the passing of the bill into law. The study will be sponsored by Hull University Teaching Hospitals Trust (HUTH).",[238,239],"Assisted Dying","Palliative Care","2026-02-16",{"date":242,"type":38},"2026-02-23",{"date":244,"type":21},"2026-03-01",{"date":246,"type":21},"2027-05-01",{"name":44,"class":45},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":46},"100377357","machine-learning-in-quantitative-stress-echocardiography-100377357","NCT04193475","Machine Learning in Quantitative Stress Echocardiography","MLQSE","Inclusion Criteria:\n\n* Clinically suitable for stress echocardiography examination\n\nExclusion Criteria:\n\n* None","20 Years","89 Years",{"count":258,"type":21},1250,"Greater diagnostic accuracy is required to find out who is at risk of a heart attack as this can reduce the requirement of more invasive downstream tests and thereby improve the patient experience and also reduce their exposure to risk. Stress echocardiography is a routine clinical test that involves using ultrasound to image the heart whilst it is under stress to assess the risk of a heart attack.\n\nThis study will focus on developing more accurate analysis tools to interpret the results of these stress echocardiographic scans. New methods will be tested to measure the function of each part of the heart muscle, using advanced analysis of the information obtained when high-frequency sound waves are bounced off the heart inside the chest. The researchers will measure and report exact heart function during stress, so that they will be able to recognise normal hearts and those with any disease. New computer methods will be developed to display any abnormality, which will make it easier for doctors to choose the best treatment for patients who are at risk.\n\nThe goals and potential benefits of this research proposal are to update the interpretation of a routinely used clinical test (stress echocardiography) to produce a reliable new method for diagnosing the precise effects of diseased arteries on the function of the heart muscle; to develop new computer graphics that adapt to show individual risks for each patient; and to implement new computer models that can be constantly updated",[62,261],"Ischaemic Heart Disease",[263,264,265,266,267,268],"Chest pain","Angina","Deformation imaging","Tissue doppler imaging","Strain","Velocity","2026-02-12",{"date":271,"type":38},"2026-02-17",{"date":273,"type":38},"2019-11-22",{"date":244,"type":21},{"name":44,"class":45},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":46},"100614549","preparatory-work-for-a-trial-of-adjuncts-to-diuretic-treatment-in-patients-hospitalised-with-heart-failure-addressing-uncertainties-and-building-consensus-100614549","NCT07281040","Preparatory Work for a Trial of Adjuncts to Diuretic Treatment in Patients Hospitalised With Heart Failure: Addressing Uncertainties and Building Consensus","Preparatory Work for a Multi-arm, Multi-stage Trial of Adjunctive Treatments in Patients Hospitalised With Heart Failure (Pre-MAMMOTH-HF)","Pre-MAMMOTH-HF","Inclusion Criteria:\n\n1. Recent hospitalisation with heart failure (\\\u003C6 months) or carer for a person with a recent hospitalisation with heart failure.\n2. Able to participate in online group discussions in English\n\nExclusion Criteria:\n\n1\\. Unable to participate in online group discussions in English",{"count":285,"type":21},10,"Aims and Objectives\n\n1. Choose which adjunctive therapies, at what dose, and for how long\n2. Choose the dose(s) of IV furosemide to be used as the comparator\n3. Choose primary and secondary outcomes\n4. Estimate recruitment and engage sites for a future trial\n\nWork package 2a methods overview\n\n1. An online survey of clinicians (doctors, nurses and pharmacists) assessing potential ability to recruit and the acceptability of each adjunct and willingness to support a trial.\n2. Evidence generated (survey and reviews) will be considered by an expert panel (N=20-25) including expert clinicians and allied health professionals who care for people with HF using a modified Delphi approach. The panel will make recommendations on all aspects of the trial design.\n3. A patient and carer panel of people with a recent hospitalisation (\\\u003C6 months) for HF will provide recommendations on trial endpoints. The patient-and-carer advisory group (PCAG) will also input into these discussions.",[288],"Heart Failure","2025-12-04",{"date":291,"type":38},"2025-12-15",{"date":293,"type":38},"2025-07-02",{"date":295,"type":21},"2026-10-01",{"name":44,"class":45},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":46},"100545019","an-observational-study-using-novel-questionnaire-to-characterize-cough-phenotypes-in-patients-with-chronic-cough-100545019","NCT06376448","An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough","Inclusion Criteria:\n\n1. Male and female patients \\> 18yrs of age\n2. Patients with a current cough of at least 8 weeks duration\n3. Patients with a clear chest X-Ray within previous 2 yrs\n4. Non- smoker\n5. Able to understand and comply with the requirements of the study and sign Informed Consent forms.\n6. Good understanding of written and spoken English -\n\nExclusion Criteria:\n\n1. Recent respiratory tract infection (\\\u003C4 weeks prior).\n2. Current smokers or ex-smokers with \\\u003C6 months' abstinence prior to Study.\n3. Any clinically significant or unstable medical or psychiatric condition that would, in the opinion of the investigator, interfere with the subject's ability to participate in the study safely.\n4. Participation in any clinical research study evaluating an investigational drug or therapy within 30 days or within 5 half-lives (whichever is longer) of the investigational drug prior to Study visit. If the subject was in an observational clinical study no washout is required.\n5. Subjects who, in the opinion of the Investigator, should not participate in the study for any other reason.",{"count":304,"type":21},60,"Cough has previously been described by the type of cough you have ie such as wet, dry, and chesty, and also by its features such as how often you are coughing its,intensity, and severity, but never has the varying patterns of cough been studied in any detail and it could be that the pattern of the cough is closely related to patient-perceived intensity, frequency and most importantly severity. Cough is a symptom and like any other symptom (such as pain) the severity of it can only be gauged by the patient experiencing it.\n\nWe have created a one-page brand newl questionnaire that shows 4 distinct cough patterns that we believe exist and an empty field designed so that patients can record a pattern of cough they experience which is not already a choice on the questionnaire. The questionnaire also records patients' experience of how frequent, and intense, the cough is, and how it disrupts their lives, on a 1-10 scale (Visual analogue scale), the sum of these scores is collated and this gives us a severity score. The first phase of the project is to determine whether 30 Chronic cough patients understand the questionnaire, and are able to complete it with little direction, and if the cough patterns we identified encompassed all pattern types. second part of the study is to look at how repeatable the questionnaire is when completed over a 6 week period.",[307],"Chronic Cough","2025-07-29",{"date":310,"type":38},"2025-08-01",{"date":312,"type":38},"2022-10-24",{"date":314,"type":21},"2025-12-10",{"name":44,"class":45},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":46},"100564273","phase-4-dermoscopy-vs-standard-marking-for-the-completeness-of-excision-of-keratinocyte-skin-cancers-the-clearmark-trial-100564273","NCT06627036","Dermoscopy vs Standard Marking for the Completeness of Excision of Keratinocyte Skin Cancers: The ClearMark Trial","Dermoscopy vs. Standard Marking Practices for the Completeness of Excision of Keratinocyte Skin Cancers: a Single-centre Randomised Controlled Trial","ClearMark","Inclusion Criteria:\n\n* Adults aged 18 years or older who are scheduled for the excision of a suspected non-melanoma skin cancer lesion as part of a day-case surgery list at Hull University Teaching Hospitals are eligible for inclusion in the study.\n\nExclusion Criteria:\n\n* Lesions that are inaccessible to dermoscopic assessment due to anatomical locations or conditions that prevent effective use of the dermatoscope.\n* Lesions that are determined to be benign or pigmented upon initial evaluation and therefore do not meet the criteria for suspected keratinocyte skin cancer.\n* Lesions scheduled for incisional, punch, or shave biopsy procedures, as these methods do not provide complete peripheral margin clearance.\n* Lesions that are histologically confirmed as benign following excision and examination by a pathologist.\n* Patients who decline to participate in the study.\n* Patients who are unable to provide informed consent due to a lack of mental capacity or other reasons.",{"count":325,"type":21},1376,[327],"PHASE4","What is the study about? This study aims to improve the success rate of removal surgery for a common type of skin cancer. We will compare two different methods of marking (drawing where to remove) the skin before removing the lump: the normal method using magnifying glasses and theatre lights, and our proposed method using a handheld magnifying device called a dermatoscope.\n\nWhy is this study important? Skin cancer is the most common cancer in the UK. Currently, up to 10-11% of surgeries do not remove all of the cancer, which means patients may need more treatment. We do not know whether using a dermatoscope can help surgeons remove all of the cancer more often or not. If it does, it could prevent patients needing more surgery or time in hospital.\n\nWhat will happen during the study? A computer will randomly allocate each participant to marking using the normal method, or using a dermatoscope. The surgery will then proceed as usual. After the surgery, patients will be asked to fill in a simple questionnaire about their thoughts. We will collect data from patients' notes to monitor the success of the surgery and any more treatments needed.\n\nWhat will we measure? We will check participants records to see if the cancer was entirely removed. This is reported by a pathologist whenever a skin lump or bump is removed. In time, we will also look at 5-year recurrence of cancer, the need for additional treatments, any problems from the marking process, how happy patients are with the process, and the time it takes to perform the marking.\n\nWhat is the pilot for? The study will need many hundreds of patients to pick up a meaningful result. Before we commit to recruiting this many people, we want to make sure that the way we run the study is acceptable. This means looking at the number of people we recruit each week, how easy it is to collect their data after their operation, and whether there are any areas that we can't use a dermatoscope, such as the curves around the eye, nose and ears. We will run the study in a smaller number of people (around 200) before deciding whether we can commit to recruiting everyone. This will also give us the chance to see whether we can run the study in more than one hospital.",[330],"Keratinocyte Skin Cancer",[332,333,334,335],"Keratinocyte Cancer","Skin Cancer","Loupe magnification","Dermoscopy","2025-01-21",{"date":338,"type":38},"2025-01-24",{"date":340,"type":38},"2024-11-21",{"date":342,"type":21},"2031-05-31",{"name":44,"class":45},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":80,"sex":16,"minAge":351,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":46},"100429079","endoscopic-severity-image-recognition-to-advance-research-and-training-in-inflammatory-bowel-disease-everest---ibd-100429079","NCT04867408","Endoscopic Severity Image Recognition to Advance Research and Training in Inflammatory Bowel Disease (EVEREST - IBD)","EVEREST - IBD: Endoscopic Severity Image Recognition to Advance Research and Training in Inflammatory Bowel Disease","Inclusion Criteria:\n\n* • Any adult patient aged 16 years or older who has consented to undergo endoscopic investigation where images are captured as part of routine clinical care.\n\nExclusion Criteria:\n\n* • Any patient under the age of 16\n\n  * Patients who are unable to give informed consent to undergo endoscopic investigation or those who do not wish their pseudo-anonymised images to be used","16 Years","99 Years",{"count":354,"type":21},4000,"To develop and train a convolutional neural network to detect and characterize disease severity of inflammatory bowel disease during endoscopy",[357],"Inflammatory Bowel Disease 1","2024-11-14",{"date":360,"type":38},"2024-11-15",{"date":362,"type":38},"2021-09-17",{"date":364,"type":21},"2031-09",{"name":44,"class":45},""]